Pacific Biosciences Of California (PACB) Restructuring Costs (2021 - 2023)

Pacific Biosciences Of California (PACB) posted Restructuring Costs of $63000.0 for Q4 2023, down 99.3% on a QoQ basis from $9.0 million in Q3 2023.

Analysis

Pacific Biosciences Of California (PACB) Restructuring Costs (2021 - 2023) Analysis & Trends

Pacific Biosciences Of California has reported Restructuring Costs for 2 years, with the latest figure at $63000.0 in Q4 2023.

On a quarterly basis, Restructuring Costs changed N/A year-over-year to $63000.0 in Q4 2023; TTM through Dec 2024 was $9.0 million, a N/A change from a year earlier, with the FY2023 full-year figure at $9.0 million, changed N/A from the prior year.
Restructuring Costs was $63000.0 for Q4 2023 at Pacific Biosciences Of California, down from $9.0 million in the prior quarter.
The five-year high for Restructuring Costs was $12.0 million in Q3 2021, with the low at $63000.0 in Q4 2023.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Thermo Fisher Scientific	224.92 Bn	220.85 Bn	8.34 Bn
2	Danaher	144.67 Bn	140.33 Bn	3.61 Bn
3	Agilent Technologies	41.02 Bn	39.26 Bn	1.04 Bn
4	Illumina	31.29 Bn	30.12 Bn	770.00 Mn
5	Revvity	13.86 Bn	12.84 Bn	416.87 Mn
6	Bio-Techne	11.27 Bn	11.01 Bn	211.39 Mn
7	Bio-Rad Laboratories	10.12 Bn	8.50 Bn	345.80 Mn
8	Repligen	9.31 Bn	8.29 Bn	110.04 Mn
9	10x Genomics	8.66 Bn	8.10 Bn	112.50 Mn
10	Pacific Biosciences Of California	400.74 Mn	163.87 Mn	12.64 Mn

Historic Data

Download Data